Dossier
stock price decline
Coverage of stock price decline in the Nexus archive.
- Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax fell 32% following updated trial data on its lead asset for bowel disease. The stock decline occurred after the company reported fresh data on its primary drug candidate.
- National Healthcare REIT Sinks 3.7% After $462 Million US IPO
National Healthcare REIT experienced a 3.7% decline in its stock price following a $462 million initial public offering (IPO) in the United States. The drop reflects market concerns or performance pressures post-listing.